We’re Moving Your Greatest Idea Forward
Have an invention? Tell us about it! Please note that public disclosures such as conference abstracts and publications may preclude our ability to protect your invention. Be sure to inform OTC of any imminent or prior disclosures!
Through our partnerships with faculty, industry, entrepreneurs and investors, ensure that Duke innovations reach the marketplace for the benefit of society and to enable future investment in Duke research and innovation.
Duke will be a leader in transferring its knowledge and innovations to the worldwide community.
Faculty & Innovators
We work together to augment the impact of your innovations, build connections with industrial, entrepreneurial, legal and investment resources and amplify the value and impact of your Duke innovations.
Duke Capital Partners
An investment network of Duke alumni, faculty, and parents which and provides its members with exciting opportunities for its members to invest in early-stage companies with a Duke connection – and for Duke-affiliated entrepreneurs to pitch their companies for potential investment.
Looking for cutting-edge technology? We welcome you to browse our list of available technologies from therapeutics to imaging and software and find one that will make a difference!
Bringing your innovation to the market requires a lot of resources. We are here to guide you on available resources at Duke and beyond that will help you realize your dream.
Duke Start-up: Warden Bio
Warden Bio is developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). The GSD gene therapy is based on research led by the lab of Dr. Priya Kishnani, Chen Family Distinguished Professor & Division Chief for Medical Genetics at Duke University, in close collaboration with Dr. Aravind Asokan, Professor & Director of Gene Therapy at Duke University and Co-Founder of StrideBio. Over the past three decades, Dr. Kishnani has built an interdisciplinary team with world-leading GSD expertise whose efforts are most notably demonstrated by the long-standing research and clinical experience that resulted in FDA approval of alglucosidase alfa (Myozyme/Lumizyme) as the...
Kishnani Priya, Aravind Asokan, Sun Baodong
Duke Start-up: Solar Unsoiled
Solar Unsoiled is an interactive, data-driven platform to optimize global solar energy production. The company is maximizing solar energy profit and reducing financial risk using predictive models to mitigate the impact of energy losses due to dust and air pollution. Solar Unsoiled targets optimization surrounding the issue of detrimental soiling losses.
Duke Start-up: Basking Biosciences Inc.
Basking Bio, founded by endovascular neurosurgeon and research scientist, Shai Nimjee, is developing a drug-antidote pair for treatment of patients with ischemic stroke using technologies founded out of Duke Professor of Surgery, Bruce Sullenger’s Cardiovascular Biology Lab. Basking Biosciences is developing the only reversible anti-thrombotic therapeutic to treat ischemic stroke. Founded based on IP licensed from Duke and Ohio State Universities, DTRI-031, Basking’s lead compound, leverages the proven aptamer technology platform developed in founder Bruce Sullenger’s lab at Duke to create a highly specific inhibitor of Von Willebrand Factor (VWF) and a paired reversal agent. This paired therapy enables rapid...
Bruce Sullenger , Shai Nimjee
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Radius Health, with its eventual partner Stemline Therapeutics/Menarini Group, licensed the cancer indications for this drug in 2017 out of the lab of Dr. Donald…
Invented at Duke 2022 brings together the university research, innovation, and entrepreneurship community
Members of the Duke research, innovation, and entrepreneurship community gathered for the annual celebration of inventions and inventors, as well as to network with each…
Duke University’s Office for Translation & Commercialization continues to grow and set new records for commercializing innovations, according to just-released fiscal year 2022 data.
2023 CSL Research Acceleration Initiative
Biotherapies. Successful applicants will receive up to $400k over 2 years. Applications due 23rd February 2023.
Anatomy of a Commercial Launch / Entrepreneurship Workshop Series
This EngEn session will provide insights based on deep domain expertise in commercial execution, external challenges to current thinking and approaches, and a proposed set of actions to build a sustainable commercial platform.
Proposals Due 2/20: Climate Research Innovation Seed Program Grants
All Duke faculty and research staff are invited to submit proposals for the first round of Climate Research Innovation Seed Program (CRISP) funding by February 20, 2023, at 5 p.m. ET.
Request for Proposal: Neuroscience Assets in Lead Generation Stage
Asset should have human/patient-based therapeutic rationale addressing the current unmet needs of the potential target population and unique selling point versus competitor assets targeting same indication or mechanism.
ARPA-E Fellows Job Opening (Spring 2023)
The Fellows identify possible breakthrough energy technologies, conduct technical and economic analyses, and help inform agency strategy and direction. During their two-year tenure, ARPA-E Fellows influence the direction of American energy innovation and engage with…
Asahi Kasei Pharma Open Innovation in 2023
Asahi Kasei is publicly calling for new proposals related to drug development research. They will offer selected candidates collaborative research opportunities, with research funding and contribution to the program through their scientists’ research activities.
2023 ARPA-E Energy Innovation Summit – Student Program
The U.S. Department of Energy’s Advanced Research Project Agency – Energy (ARPA-E) – would like to invite graduate-level students from Duke University to participate in the Student Program at the 2023 ARPA-E Energy Innovation Summit. The Summit…
OUP Data Licensing Webinar Series
Wondering about or currently working in the complex world of licensing patient data at academic institutions? Come join your colleagues for a three-part webinar series on patient data licensing.